212 related articles for article (PubMed ID: 23442043)
1. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.
Derenzini E; Younes A
Expert Opin Investig Drugs; 2013 Jun; 22(6):775-85. PubMed ID: 23442043
[TBL] [Abstract][Full Text] [Related]
2. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
Jain T; Mesa R
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1101-1108. PubMed ID: 27598824
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
Younes A; Romaguera J; Fanale M; McLaughlin P; Hagemeister F; Copeland A; Neelapu S; Kwak L; Shah J; de Castro Faria S; Hart S; Wood J; Jayaraman R; Ethirajulu K; Zhu J
J Clin Oncol; 2012 Nov; 30(33):4161-7. PubMed ID: 22965964
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
William AD; Lee AC; Blanchard S; Poulsen A; Teo EL; Nagaraj H; Tan E; Chen D; Williams M; Sun ET; Goh KC; Ong WC; Goh SK; Hart S; Jayaraman R; Pasha MK; Ethirajulu K; Wood JM; Dymock BW
J Med Chem; 2011 Jul; 54(13):4638-58. PubMed ID: 21604762
[TBL] [Abstract][Full Text] [Related]
5. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
Tremblay D; Mascarenhas J
Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive review of pacritinib in myelofibrosis.
Verstovsek S; Komrokji RS
Future Oncol; 2015; 11(20):2819-30. PubMed ID: 26367195
[TBL] [Abstract][Full Text] [Related]
7. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.
Hart S; Goh KC; Novotny-Diermayr V; Hu CY; Hentze H; Tan YC; Madan B; Amalini C; Loh YK; Ong LC; William AD; Lee A; Poulsen A; Jayaraman R; Ong KH; Ethirajulu K; Dymock BW; Wood JW
Leukemia; 2011 Nov; 25(11):1751-9. PubMed ID: 21691275
[TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
Yang EG; Mustafa N; Tan EC; Poulsen A; Ramanujulu PM; Chng WJ; Yen JJ; Dymock BW
J Med Chem; 2016 Sep; 59(18):8233-62. PubMed ID: 27541357
[TBL] [Abstract][Full Text] [Related]
9. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
10. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ
J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243
[TBL] [Abstract][Full Text] [Related]
11. Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies.
Scott LM; Gandhi MK
Blood Rev; 2015 Nov; 29(6):405-15. PubMed ID: 26123794
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3).
Poulsen A; William A; Blanchard S; Lee A; Nagaraj H; Wang H; Teo E; Tan E; Goh KC; Dymock B
J Comput Aided Mol Des; 2012 Apr; 26(4):437-50. PubMed ID: 22527961
[TBL] [Abstract][Full Text] [Related]
13. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
Jensen KV; Cseh O; Aman A; Weiss S; Luchman HA
PLoS One; 2017; 12(12):e0189670. PubMed ID: 29253028
[TBL] [Abstract][Full Text] [Related]
14. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
Diaz AE; Mesa RA
Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894
[TBL] [Abstract][Full Text] [Related]
15. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
16. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
[TBL] [Abstract][Full Text] [Related]
17. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
18. Pacritinib: a new agent for the management of myelofibrosis?
Beauverd Y; McLornan DP; Harrison CN
Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
[TBL] [Abstract][Full Text] [Related]
19. Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway.
Mao F; Gao L; Liu L; Tang Y
J Chemother; 2024 May; 36(3):238-248. PubMed ID: 37916436
[TBL] [Abstract][Full Text] [Related]
20. Studies on the anti-psoriasis effects and its mechanism of a dual JAK2/FLT3 inhibitor flonoltinib maleate.
Zhu J; Yang T; Tang M; Yang Z; Pei H; Ye H; Tang Y; Cheng Z; Lin P; Chen L
Biomed Pharmacother; 2021 May; 137():111373. PubMed ID: 33761599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
